-
Mashup Score: 2Exploring strategies to mitigate T-cell exhaustion: treatment-free intervals & small molecules - 1 year(s) ago
In this video, Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, shares some insights into how chronic treatment with…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Axicabtagene Ciloleucel Leads to ‘Continued Durable Responses’ in ZUMA-5 | Blood Cancers Today - 1 year(s) ago
Axicabtagene ciloleucel led to “continued durable responses” in patients with relapsed/refractory indolent non-Hodgkin lymphoma in the ZUMA-5 trial.
Source: Blood Cancers TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Exploring the use of BTK inhibitors as a strategy to increase the efficacy of CAR-T cells - 1 year(s) ago
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, highlights ongoing research exploring the use of…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Exploring strategies to mitigate T-cell exhaustion: treatment-free intervals & small molecules - 1 year(s) ago
In this video, Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, shares some insights into how chronic treatment with…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Study Validates Presence of Immunotherapeutic Targets for Multiple Myeloma | Blood Cancers Today - 1 year(s) ago
A new study verified the presence of three surface antigens, BCMA, ETRB, and FCRL5, on multiple myeloma cells. ETRB could emerge as potential CAR-T target.
Source: Blood Cancers TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Endothelin receptor B, a novel tumor-specific antigen found on multiple myeloma cells, could emerge as a potential CAR-T target, according to a study presented by researchers from the @UniversiteLiege during the @TheEBMT-@EHA_Hematology #CART23 meeting. https://t.co/p0G4g1I2Ov https://t.co/FmIFjfYhyZ
-
-
Mashup Score: 0
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares some insights into how the treatment and management of cytokine…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1The main aims of the T2EVOLVE Consortium - 1 year(s) ago
Sonia Guedan, PhD, IDIBAPS-Hospital Clinic Barcelona, Barcelona, Spain, shares some insights into the T2EVOLVE Consortium, which aims to accelerate the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Challenges with diagnosing CAR-HLH and how this impacts patients receiving CAR-T therapy - 1 year(s) ago
Muhammad Gohar Maqbool, MRCP (UK); MRCPE; FRACP; FRCPA, University Hospital Bristol NHS Foundation Trust, Bristol, UK, discusses challenges with diagnosing…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Pembrolizumab Demonstrates Good Safety After CAR T-Cell Therapy in R/R DLBCL | Blood Cancers Today - 1 year(s) ago
A new study supports the safety of salvage therapy with pembrolizumab after CD19-directed CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma.
Source: Blood Cancers TodayCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, gives an overview…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Learn more about strategies being explored to mitigate T-cell exhaustion in our interview with @MSubklewe of @LMU_Muenchen: 👉https://t.co/AR6sg2V0lC👈 @TheEBMT @EHA_Hematology #CART23 #HemOnc #CARTcell #ImmunoOnc